利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.025 秒)

    Process for physicochemically producing glycogen and glycogen obtained thereby
    1.
    发明申请
    Process for physicochemically producing glycogen and glycogen obtained thereby 有权
    由此获得的物理化学产生糖原和糖原的方法

    公开(公告)号：US20050048142A1

    公开(公告)日：2005-03-03

    申请号：US10497694

    申请日：2002-12-06

    申请人： Kazuyoshi Matsunaga ,  Takafumi Ishihara

    发明人： Kazuyoshi Matsunaga ,  Takafumi Ishihara

    IPC分类号： C08B37/00 ,  C08B37/18 ,  A61K31/715 ,  A61K35/78

    CPC分类号： C08B37/0009

    摘要： A method of producing glycogen is provided. The method comprises the step of heat- and pressure-treating a sugar-containing material under acidic conditions. The sugar-containing material is a polysaccharide or an oligosaccharide. Alternatively, the sugar-containing material is a plant material selected from the group consisting of Panax notoginseng, Yun Nan San-chi powder (trademark), Panax ginseng, wheat flour, soybean, soy flour, shiitake, and coffee extract residue. Representatively, the glycogen includes a molecule having a molecular weight of 10,000 or less. The glycogen has a specific rotation of [α]D+197° and anomeric proton peaks at 5.37 ppm and 4.95 to 5.33 ppm in 1H NMR spectra.

    摘要翻译： 提供了制备糖原的方法。 该方法包括在酸性条件下对含糖材料进行加热和加压处理的步骤。 含糖材料是多糖或寡糖。 或者，含糖材料是选自三七，云南三奇粉（商标），人参，小麦粉，大豆，大豆粉，香菇和咖啡提取物残渣的植物材料。 代表性地，糖原包括分子量为10,000以下的分子。 在1 H NMR光谱中，糖原具有αD+ 197°的比旋光度和5.37ppm和4.95-5.33ppm的异质质子峰。

    Pyrroloazepine derivatives
    2.
    发明授权
    Pyrroloazepine derivatives 失效
    吡咯并氮衍生物

    公开(公告)号：US5416082A

    公开(公告)日：1995-05-16

    申请号：US195019

    申请日：1994-02-14

    申请人： Akira Mizuno ,  Hidetsura Cho ,  Mikiko Hamaguchi ,  Toshio Tatsuoka ,  Takafumi Ishihara

    发明人： Akira Mizuno ,  Hidetsura Cho ,  Mikiko Hamaguchi ,  Toshio Tatsuoka ,  Takafumi Ishihara

    IPC分类号： A61K31/55 ,  A61P9/00 ,  A61P9/04 ,  A61P9/12 ,  A61P43/00 ,  C07D487/04

    CPC分类号： C07D487/04

    摘要： Disclosed herein are pyrroloazepine derivatives having anti-.alpha..sub.1 activity and anti-serotonin activity represented by the following formula (I): ##STR1## wherein R means a hydrogen atom, a linear or branched C.sub.1-6 alkyl group or a C.sub.7-10 aralkyl group, A denotes a linear or branched C.sub.2-10 alkylene, alkenylene or alkynylene group, Z stands for O, NOR.sub.1 or NOCOR.sub.5 in which R.sub.1 and R.sub.5 is a hydrogen atom or an alkyl, aryl or aralkyl group, and Y means a particular piperidinyl or pyrrolidinyl group; and salts thereof. Their preparation processes are also disclosed.

    摘要翻译： 本文公开了具有由下式（I）表示的抗α1活性和抗5-羟色胺活性的吡咯并氮衍生物：直链或支链C 1-6烷基或C 7-10芳烷基，A表示直链或支链C 2-10 亚烷基，亚烯基或亚炔基，Z代表O，NOR1或NOCOR5，其中R1和R5是氢原子或烷基，芳基或芳烷基，Y表示特定的哌啶基或吡咯烷基; 及其盐。 还公开了它们的制备方法。

    Pyrrolizidine derivative and pharmaceutical composition thereof
    4.
    发明授权
    Pyrrolizidine derivative and pharmaceutical composition thereof 失效
    吡咯烷啶衍生物及其药物组合物

    公开(公告)号：US4751232A

    公开(公告)日：1988-06-14

    申请号：US703913

    申请日：1985-02-21

    申请人： Fumio Satoh ,  Keiyu Shima ,  Takafumi Ishihara

    发明人： Fumio Satoh ,  Keiyu Shima ,  Takafumi Ishihara

    IPC分类号： A61K31/40 ,  A61P9/06 ,  C07D487/04 ,  C07D487/06

    CPC分类号： C07D487/04

    摘要： A novel pyrrolizidine derivative of the formula, ##STR1## which has potent antiarrhythmic activity and low toxicity is produced. The derivative can be synthesized: by acylating 2,6-xylidine to protect the amino group, nitrating the protected xylidine to introduce a nitro group at 3-position, reducing the nitro group to an amino group, followed by diazotizing and hydrolyzing, and then the resulted 3-hydroxy-2,6-dimethylaniline being condensed with 8-halocarbonylmethylpyrrolizidine; or by nitrating N-(2',6'-dimethyl)phenyl-8-pyrrolizidineacetamide to introduce a nitro group at 3'-position, reducing the nitro group to amino group, diazotizing the amino group and hydrolyzing the diazonium compound.

    摘要翻译： 产生具有强力抗心律不齐活性和低毒性的式“IMAGE”的新型吡咯烷啶衍生物。 可以合成衍生物：通过酰化2,6-二甲苯来保护氨基，硝化保护的二甲苯胺在3-位上引入硝基，将硝基还原成氨基，然后进行重氮化和水解，然后 所得3-羟基-2,6-二甲基苯胺与8-卤代羰基甲基吡咯烷酮缩合; 或通过硝化N-（2'，6'-二甲基）苯基-8-吡咯烷啶酮乙酰胺在3'-位引入硝基，将硝基还原成氨基，重氮化氨基并水解重氮化合物。

    Methods of treating hypertension
    5.
    发明授权
    Methods of treating hypertension 有权
    治疗高血压的方法

    公开(公告)号：US07820667B2

    公开(公告)日：2010-10-26

    申请号：US11209673

    申请日：2005-08-24

    申请人： Takafumi Ishihara ,  Yoshiharu Kanayama ,  Mikio Okamura ,  Junichi Yoshikawa ,  Haruo Shintaku

    发明人： Takafumi Ishihara ,  Yoshiharu Kanayama ,  Mikio Okamura ,  Junichi Yoshikawa ,  Haruo Shintaku

    IPC分类号： A61K31/519

    CPC分类号： A61K31/525 ,  A61K31/519 ,  C07D475/04

    摘要： It is an object of the present invention to provide a therapeutic agent for effectively preventing or ameliorating diseases caused by dysfunction of NOS.The present invention provides a pharmaceutical composition for preventing and/or treating diseases associated with dysfunction of NOS, comprising as an effective ingredient, a compound of the formula (I): wherein R1 and R2 each represents a hydrogen atom or, taken together with each other, represent a single bond, while R3 represents —CH(OH)CH(OH)CH3, —CH(OCOCH3)CH(OCOCH3)CH3, —CH3, —CH2OH, or a phenyl group when R1 and R2 each represents a hydrogen atom, or —COCH(OH)CH3 when R1 and R2 together represent a single bond, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明的目的是提供一种有效预防或改善由NOS功能障碍引起的疾病的治疗剂。 本发明提供了用于预防和/或治疗与NOS功能障碍有关的疾病的药物组合物，其包含作为有效成分的式（I）化合物：其中R 1和R 2各自表示氢原子，或与 另一个表示单键，而当R 1和R 2各自表示氢时，R 3表示-CH（OH）CH（OH）CH 3，-CH（OCOCH 3）CH（OCOCH 3）CH 3，-CH 3，-CH 2 OH或苯基 原子或-COCH（OH）CH 3，或者其中R 1和R 2一起表示单键时，或其药学上可接受的盐。

    Prophylactic or therapeutic agents for diseases associated with dysfunction of NOS
    6.
    发明申请
    Prophylactic or therapeutic agents for diseases associated with dysfunction of NOS 有权
    与NOS功能障碍有关的疾病的预防或治疗药物

    公开(公告)号：US20060009458A1

    公开(公告)日：2006-01-12

    申请号：US11209673

    申请日：2005-08-24

    申请人： Takafumi Ishihara ,  Yoshiharu Kanayama ,  Mikio Okamura ,  Junichi Yoshikawa ,  Haruo Shintaku

    发明人： Takafumi Ishihara ,  Yoshiharu Kanayama ,  Mikio Okamura ,  Junichi Yoshikawa ,  Haruo Shintaku

    IPC分类号： A61K31/525

    CPC分类号： A61K31/525 ,  A61K31/519 ,  C07D475/04

    摘要： It is an object of the present invention to provide a therapeutic agent for effectively preventing or ameliorating diseases caused by dysfunction of NOS. The present invention provides a pharmaceutical composition for preventing and/or treating diseases associated with dysfunction of NOS, comprising as an effective ingredient, a compound of the formula (I): wherein R1 and R2 each represents a hydrogen atom or, taken together with each other, represent a single bond, while R3 represents —CH(OH)CH(OH)CH3, —CH(OCOCH3)CH(OCOCH3)CH3, —CH3, —CH2OH, or a phenyl group when R1 and R2 each represents a hydrogen atom, or —COCH(OH)CH3 when R1 and R2 together represent a single bond, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明的目的是提供一种有效预防或改善由NOS功能障碍引起的疾病的治疗剂。 本发明提供了用于预防和/或治疗与NOS功能障碍有关的疾病的药物组合物，其包含作为有效成分的式（I）化合物：其中R 1和R 2 2各自表示氢原子，或彼此一起表示单键，而R 3表示-CH（OH）CH（OH）CH 3， CH 3，-CH（OCOCH 3）CH（OCOCH 3）CH 3，-CH 3 - ， - CH 2 OH或当R 1和R 2各自表示氢原子时的苯基，或-COCH（OH）CH 3 。

    2,6-Dimethyl-3N,5-disubstituted-4-(substituted phenyl)3,4-dihydropyrimidine compounds and a method for treating disorders of cardiocircular system
    10.
    发明授权
    2,6-Dimethyl-3N,5-disubstituted-4-(substituted phenyl)3,4-dihydropyrimidine compounds and a method for treating disorders of cardiocircular system 失效
    2,6-二甲基-3N，5-二取代-4-（取代苯基）3,4-二氢嘧啶化合物和治疗心脏循环系统疾病的方法

    公开(公告)号：US4683234A

    公开(公告)日：1987-07-28

    申请号：US708885

    申请日：1985-03-06

    申请人： Hidetsura Cho ,  Kazuo Aisaka ,  Fumio Sato ,  Takafumi Ishihara

    发明人： Hidetsura Cho ,  Kazuo Aisaka ,  Fumio Sato ,  Takafumi Ishihara

    IPC分类号： C07D239/20 ,  A61K31/505

    CPC分类号： C07D239/20

    摘要： N-substituted 3,4-dihydropyrimidine derivatives of the formula: ##STR1## wherein X.sup.1, X.sup.2 and X.sup.3 are the same or different and are hydrogen, nitro, halogen, cyano, trifluoromethyl, methylthio or lower alkoxy;R.sup.1 is (C.sub.1 -C.sub.13) straight or branched alkoxy, (C.sub.4 -C.sub.12) straight or branched alkenyloxy, (C.sub.5 -C.sub.8) straight or branched alkynyloxy, (C.sub.1 -C.sub.4) straight or branched alkyl, (C.sub.3 -C.sub.6) cycloalkyl,--O--(CH.sub.2).sub.n --A wherein n is 1, 2 or 3, A is cyclopropyl, cyclobutyl, cyclopentyl, or (C.sub.1 -C.sub.3) haloalkyl,--O--(CH.sub.2).sub.m --O--B wherein m is 1, 2, 3 or 4, B is (C.sub.1 -C.sub.3) alkyl, or--O--(CH.sub.2).sub.l --D wherein l is an integer from zero to 8, D is phenyl or substituted phenyl;R.sup.2 is (C.sub.1 -C.sub.12) straight or branched alkyl, (C.sub.4 -C.sub.7) straight or branched alkenyl, --(CH.sub.2).sub.p --E wherein p is 1, 2 or 4, E is cyclopropyl, cyclobutyl or cyclopentyl, ##STR2## wherein q is 2, 3 or 4, G and J are the same or different and are phenyl, methyl, ethyl, isopropyl, benzyl, phenethyl, methoxycarbonyl or ethoxycarbonyl, or --(CH.sub.2).sub.r --O--L wherein r is 1 or 2, L is methyl, ethyl or phenyl, with the proviso that wherein R.sup.1 is methoxy or ethoxy, R.sup.2 is neither methyl nor ethyl, and pharmaceutically acceptable acid addition salts thereof are useful as agents for treating disorders of the cardiovascular system, for example, hypotensive agents, agents for ameriolation of brain circulation and anti-angina pectoris agents.Processes for producing the above compounds economically and effectively are also disclosed.

    摘要翻译： 下式的N-取代的3,4-二氢嘧啶衍生物：其中X 1，X 2和X 3相同或不同，为氢，硝基，卤素，氰基，三氟甲基，甲硫基或低级烷氧基; （C1-C13）直链或支链烷氧基，（C4-C12）直链或支链烯氧基，（C5-C8）直链或支链炔氧基，（C1-C4）直链或支链烷基，（C3-C6）环烷基， O-（CH 2）n A，其中n为1,2或3，A为环丙基，环丁基，环戊基或（C 1 -C 3）卤代烷基，-O-（CH 2）mOB，其中m为1,2,3或4，B 是（C 1 -C 3）烷基或-O-（CH 2）l D，其中l是0至8的整数，D是苯基或取代的苯基; R2是（C1-C12）直链或支链烷基，（C4-C7）直链或支链烯基， - （CH2）pE其中p是1,2或4，E是环丙基，环丁基或环戊基，其中q是 2,3或4中，G和J相同或不同，为苯基，甲基，乙基，异丙基，苄基，苯乙基，甲氧基羰基或乙氧基羰基，或 - （CH 2）r R R，其中r为1或2，L为甲基，乙基 或苯基，条件是其中R 1是甲氧基或乙氧基，R 2既不是甲基也不是乙基，其药学上可接受的酸加成盐可用作治疗心血管系统病症的药剂，例如降血压剂， 脑循环和抗心绞痛药物。 还公开了经济有效地生产上述化合物的方法。